[
  {
    "ts": null,
    "headline": "Zimmer Biomet Holdings Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Zimmer Biomet Holdings Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=17a401be84205365a8fb4ef469788ec80120b7502f7e7c928bfec9e360e93dfa",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755191220,
      "headline": "Zimmer Biomet Holdings Inc. stock underperforms Thursday when compared to competitors",
      "id": 136398764,
      "image": "",
      "related": "ZBH",
      "source": "MarketWatch",
      "summary": "Zimmer Biomet Holdings Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=17a401be84205365a8fb4ef469788ec80120b7502f7e7c928bfec9e360e93dfa"
    }
  },
  {
    "ts": null,
    "headline": "Zimmer Biomet’s Q2 Earnings Call: Our Top 5 Analyst Questions",
    "summary": "Zimmer Biomet’s second quarter results were met with a positive market response, reflecting successful execution on new product launches and meaningful contributions from recent M&A activity. Management attributed the quarter’s outperformance to strong U.S. growth in hip and knee implants, as well as sustained momentum in the S.E.T. (Sports Medicine, Extremities, and Trauma) segment. CEO Ivan Tornos emphasized, “Our U.S. Hips business drove strong results... and S.E.T. reported another solid mid",
    "url": "https://finnhub.io/api/news?id=d0114bab759e756be8f70aacfa93b07ee810e9d4086747f2ebabda72c3d6e86b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1755149626,
      "headline": "Zimmer Biomet’s Q2 Earnings Call: Our Top 5 Analyst Questions",
      "id": 136345164,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ZBH",
      "source": "Yahoo",
      "summary": "Zimmer Biomet’s second quarter results were met with a positive market response, reflecting successful execution on new product launches and meaningful contributions from recent M&A activity. Management attributed the quarter’s outperformance to strong U.S. growth in hip and knee implants, as well as sustained momentum in the S.E.T. (Sports Medicine, Extremities, and Trauma) segment. CEO Ivan Tornos emphasized, “Our U.S. Hips business drove strong results... and S.E.T. reported another solid mid",
      "url": "https://finnhub.io/api/news?id=d0114bab759e756be8f70aacfa93b07ee810e9d4086747f2ebabda72c3d6e86b"
    }
  }
]